Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

ClinicalTrials.gov ID: NCT06784752

Public ClinicalTrials.gov record NCT06784752. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients Newly Diagnosed With Grade 1 and Grade 2 (Ki-67 <10%) Advanced GEP-NET With High Disease Burden (NETTER-3)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+), well differentiated Grade1 and Grade 2 (G1 and G2) (Ki-67 \<10%) advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with high disease burden

Study identification

NCT ID: NCT06784752
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Novartis Pharmaceuticals; Industry
Enrollment: 240 participants

Conditions and interventions

Conditions

Interventions

[177Lu]Lu-DOTA-TATE Radiation
Octreotide LAR Drug

Radiation · Drug

Eligibility (public fields only)

Age range: 12 Years to 100 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 30, 2025 (Actual)
Primary completion: Dec 8, 2028 (Estimated)
Completion: Jan 23, 2034 (Estimated)
Last update posted: Sep 11, 2026

2025 – 2034

United States locations

U.S. sites: 20
U.S. states: 14
U.S. cities: 19

Facility	City	State	ZIP	Site status
Mayo Clinic Arizona	Scottsdale	Arizona	85259	Recruiting
Highlands Oncology Group	Fayetteville	Arkansas	72703	Recruiting
Rocky Mountain Cancer Centers	Denver	Colorado	80218	Recruiting
Hartford Hospital	Hartford	Connecticut	06102	Recruiting
Yale New Haven Hospital	New Haven	Connecticut	06520	Recruiting
Mayo Clinic Jacksonville	Jacksonville	Florida	32224	Recruiting
AdventHealth	Orlando	Florida	32804	Recruiting
Piedmont Healthcare	Atlanta	Georgia	30318	Recruiting
Winship Cancer Institute	Atlanta	Georgia	30322	Recruiting
St Elizabeth Healthcare	Edgewood	Kentucky	41017	Recruiting
LSU Medical Center	New Orleans	Louisiana	70112	Recruiting
Henry Ford Hospital	Detroit	Michigan	48202-2689	Recruiting
Mount Sinai Medical Center	New York	New York	10029-6574	Recruiting
Tennessee Oncology	Nashville	Tennessee	37203	Recruiting
TxO Austin Midtown	Austin	Texas	78705	Active, not recruiting
Texas Oncology	Dallas	Texas	75251	Recruiting
Virginia Cancer Specialists	Fairfax	Virginia	22031	Recruiting
Virginia Oncology Associates	Norfolk	Virginia	23502	Recruiting
Blue Ridge Cancer Center	Wytheville	Virginia	24382	Recruiting
Northwest Medical Specialties	Tacoma	Washington	98405	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 47 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06784752, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 11, 2026 · Synced Oct 17, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06784752 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →